Benjamin Davies is a recent graduate from the College of Pharmacy, who works as a Toxicology Fellow at the Utah Poison Control Center.... Read More
The project uses preclinical seizure models and neuroscience techniques to help develop new antiepileptic agents. Some 800-1000 novel compounds per year are evaluated against conventional drugs for anticonvulsant efficacy and potency, neurotoxicity, effect on liver function, and mechanism of action. Promising compounds, which exhibit a high level and/or unusual spectrum of anticonvulsant activity with superior therapeutic potential, are selected for detailed toxicology studies and subsequent clinical trials in epileptic patients. The project has been continually funded since 1975 and every new anticonvulsant introduced to clinical use in the USA during the past 40 years has been evaluated in this research program.
The program is an integral part of the Department of Pharmacology and Toxicology and, as such, provides a site for research training of undergraduate students, departmental graduate students and postdoctoral fellows. Faculty aligned with the program also provide instruction to professional students in the College of Pharmacy and the School of Medicine.
ADD's College of Pharmacy’s Program Awarded $19.5M Contract Renewal To Identify Compounds for Treating Therapy-Resistant Epilepsy
The PLS & Rho Chi Induction Ceremony took place on September 19, 2018.... Read More
Gregory Skedros graduated from the University of Utah College of Pharmacy in 1950. ... Read More
Kappa Psi Epsilon Chi hosted a food drive at Smiths... Read More
The Maliheh Free Clinic ribbon cutting ceremony took place on Wednesday, September 2018.... Read More
Researchers at University of Utah Health found that ADHD patients had an increased risk of developing Parkinson’s and Parkinson-like diseases than individuals with no ADHD history. ... Read MoreInternal Medicine,Psychiatry